Kidney Care: Dapagliflozin in Patients With Chronic Kidney Disease
hosted byConnect Educate Impact (CEI)
Kidney Care: Dapagliflozin in Patients With Chronic Kidney Disease is organized by Connect Educate Impact (CEI).
Initial Release Date: June 9, 2021
Planned Expiration Date: June 9, 2024
Description:
Chronic kidney disease (CKD) affects nearly 15% of US adults and is associated with diminished quality of life and reduced life expectancy. June's Journal Club examines new, favorable clinical trial data on dapagliflozin use in patients with CKD to improve renal outcomes and provide glycemic control.
Objectives:
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
• Describe the mechanism of action and clinical pearls of dapagliflozin
• Compare and contrast dapagliflozin with other available sodium-glucose co-transporter 2 (SGLT2) inhibitors
• Discuss clinical trial data on dapagliflozin’s effect on renal outcomes
• Identify patients who are candidates to receive dapagliflozin
• Develop a conclusion for the clinical appropriateness of care based on a clinical trial
